WeVote
Log In

Bill

Bill

HB 127

Pharmaceuticals; prohibiting the Board of Pharmacy from disciplining pharmacists who recommend off-label use of a drug; allowing over-the-counter sale of Ivermectin and Hydroxychloroquine.

2026 Regular Session Introduced by Chip Brown

Bill prohibits pharmacy board discipline of off-label drug recommendations and permits over-the-counter sales of ivermectin and hydroxychloroquine without prescriptions.

Read for the first time and referred to the House Committee on Health
#occupationallicensingboards
0
WeVote Research Nonpartisan
Bill Summary · HB 127

Legislative bill overview

HB 127 would prohibit the Alabama Board of Pharmacy from disciplining pharmacists who recommend off-label drug uses and would allow over-the-counter sales of ivermectin and hydroxychloroquine without prescription requirements. The bill removes regulatory oversight from pharmacy boards regarding off-label recommendations and reclassifies two specific drugs from prescription-only to OTC status.

Why is this important

Off-label drug use occurs when medications approved for one condition are used for another, a practice that exists in legitimate medicine but lacks the same safety testing for alternative uses. Allowing unrestricted OTC access to ivermectin and hydroxychloroquine—drugs that gained attention during COVID-19 despite limited evidence for that use—could increase unmonitored consumption and complicate patient safety tracking. This directly affects how pharmacists can be held accountable for their recommendations and the regulatory framework governing medication access.

Potential points of contention

  • Patient safety concerns: Removing Board of Pharmacy discipline authority eliminates a regulatory check on pharmacist recommendations, potentially allowing promotion of unproven treatments without professional consequences
  • Scientific evidence standards: Ivermectin and hydroxychloroquine have limited clinical evidence supporting COVID-19 and other off-label uses promoted during the pandemic; unrestricted access may normalize unsubstantiated treatments
  • Pharmacist professional liability: Protecting pharmacists from discipline while allowing off-label recommendations could create legal ambiguity about accountability if patients experience adverse outcomes from those recommendations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.